U.S. Healthtech Stock News

Wondering if Paycom Software at around US$138 a share is a bargain or a value trap? This article walks through what the current price actually implies. The stock has shown a 9.2% return over the last 7 days and 11.4% over the last 30 days. Yet year to date it sits at a 9.2% loss and a 44.0% loss over the past year, which naturally raises questions about risk and potential recovery. Recent coverage has focused on how Paycom Software fits into the broader professional services and software...

In late April 2026, FactSet Research Systems Inc. and J.P. Morgan announced the launch of a Whole Portfolio Distribution solution, giving institutional investors a unified, automated view of portfolios across asset classes and data sources through FactSet, powered by Fusion by J.P. Morgan and already supporting US$62.50 billion in Assets under Analysis. In early May 2026, FactSet Research Systems Inc. also approved a higher quarterly dividend of US$1.16 per share payable on June 18, 2026,...

Equifax (EFX) stock has been moving without a clear single news catalyst, leaving investors focused on its recent share performance, current valuation signals, and the latest snapshot of its business fundamentals. See our latest analysis for Equifax. At a share price of $175.62, Equifax has seen a 1-day share price return of 1.40%. Its year to date share price return of 17.95% and 1-year total shareholder return of 34.65% indicate changing momentum following earlier weakness. If you are...

CTS (CTS) has caught investor attention after first quarter 2026 earnings exceeded analyst expectations and management raised full year sales guidance, prompting closer scrutiny of what is driving the stock at recent highs. See our latest analysis for CTS. The recent 1 month share price return of 21.01% and year to date share price return of 36.49% suggest momentum has been building, supported by first quarter earnings, raised 2026 sales guidance and continued buybacks. The 1 year total...

VICI Properties (VICI) just posted first quarter 2026 results, reporting revenue of US$1.02b and net income of US$872.39m, and raised full year AFFO guidance on the back of acquisitions and lending activity. See our latest analysis for VICI Properties. At a share price of US$28.79, VICI’s 30 day share price return of 3.45% contrasts with a 1 year total shareholder return of 3.24% decline. This suggests recent momentum is improving after a softer year, as investors weigh the raised AFFO...

Multiple securities fraud class action lawsuits have been filed against Pinterest (NYSE:PINS), targeting the company and certain executives. The suits claim Pinterest misled investors about advertising revenue pressures, the effects of U.S. tariffs, and upcoming restructuring plans. These cases are at an early stage, with a lead plaintiff deadline still pending. Pinterest runs a visual discovery platform that connects users with products and ideas, and its business model relies heavily on...

Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch. See our latest analysis for Schrödinger. Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of...

With no clear single event driving headlines, Archer Aviation (ACHR) has still drawn attention as the stock shifted from a recent monthly gain to a decline over the past three months and the past year. See our latest analysis for Archer Aviation. Archer Aviation's recent share price return shows short term momentum, with a 7 day gain of 9.41% and a 30 day gain of 17.60%. However, this follows a 90 day share price decline of 13.97% and a 1 year total shareholder return of 28.31% in the red...

ACM Research (ACMR) opened 2026 with Q1 revenue of US$231.3 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$960.2 million and EPS of US$1.40 that frame the latest quarterly print. Over the past six quarters, the company has seen quarterly revenue range from US$172.3 million to US$269.2 million and basic EPS move between US$0.12 and US$0.56, giving investors a clear view of how top line and per share earnings have tracked into the current TTM profile. With...

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...

Assurant (AIZ) just paired a strong Q1 2026 earnings beat with higher full year guidance and continued share repurchases, putting the spotlight on how its Global Lifestyle driven momentum might affect the stock. See our latest analysis for Assurant. Despite the strong Q1 surprise and ongoing buybacks, Assurant’s recent trading has been mixed, with a 6.86% 1 month share price return but a 1.65% year to date share price decline. In contrast, the 1 year total shareholder return of 21.86% and 3...

Earnings picture during a key regulatory phase Vera Therapeutics (VERA) reported a first quarter net loss of US$121.03 million, compared with US$51.69 million a year earlier, as it pushes atacicept toward potential approval for IgA nephropathy. Basic and diluted loss per share from continuing operations came in at US$1.69, versus US$0.81 in the prior year period. This provides a snapshot of how much capital the company is currently investing ahead of the July 7, 2026 FDA decision. See our...

What PNC’s Recent Returns Tell You PNC Financial Services Group (PNC) has moved in different directions across timeframes, with a 1 day return of about a 1.4% decline, losses over the past 3 months, and a 1 year total return of 35.9%. See our latest analysis for PNC Financial Services Group. Recent share price moves have cooled slightly, with a 30 day share price return of 2.5% against a 90 day share price return of a 9.6% decline, while the 1 year total shareholder return of 36.0% and 3...

Wondering if Labcorp Holdings at around US$258 a share still offers value, or if most of the opportunity is already priced in? This article walks through the key signals you can use to judge that for yourself. The stock has been fairly steady over the last week with a 0.5% return, has a 4.1% decline over the past month, yet sits on a 4.8% return over 1 year and 41.6% over 3 years. This raises the question of whether the current price reflects the business fundamentals. Recent headlines...

How Avery Dennison (AVY) Has Been Trading Recently Avery Dennison (AVY) has seen mixed share performance recently, with a 0.7% decline over the past day, a 1% gain over the past week, and a 1.2% decline over the past month. Over the past 3 months, the stock shows a 13.6% decline, with a year to date return of negative 9.3% and a 1 year total return of negative 2.3%. Longer term, the 3 year total return stands at 1.5%, while the 5 year total return is negative 18.3%. See our latest analysis...

In early May 2026, Jackson Financial Inc. reported first-quarter 2026 results showing revenue of US$2,902 million and a net loss of US$424 million, while also continuing to return capital through dividends and share repurchases under its multi-year buyback program. Beneath the headline loss, the company highlighted strong retail annuity momentum, a very large share repurchase completion since 2021, and a new TPG partnership aimed at supporting product diversification and capital...

Ubiquiti (UI) has put up another big quarter, with Q2 2026 revenue of US$814.9 million and basic EPS of US$3.86, while trailing 12 month EPS sits at US$14.69 on revenue of about US$3.0 billion and earnings growth over that period is described as a 99.7% jump. The company has seen quarterly revenue move from US$599.9 million and EPS of US$2.26 in Q2 2025 to US$814.9 million and EPS of US$3.86 in Q2 2026, and trailing 12 month net profit margin is now stated at 29.9% versus 20.7% a year...

Lattice Semiconductor reported past Q1 2026 results with revenue of US$170.9 million and net income of US$21.82 million, beating market expectations and issuing Q2 revenue guidance of US$175 million to US$195 million. The company also announced an agreement to acquire AMI for about US$1.65 billion, aiming to combine low-power FPGAs with firmware and manageability software to broaden its role in AI servers and cloud infrastructure. Next, we’ll examine how this earnings beat and AMI...

Navios Maritime Partners L.P. recently announced that its Board of Directors approved a cash distribution of US$0.06 per unit for the quarter ended March 31, 2026, a 20% increase over the prior quarter, payable on May 14, 2026 to holders of record as of May 11, 2026. This higher quarterly payout, equivalent to an annualized US$0.24 per unit, highlights management’s willingness to return more cash to unitholders and may influence how investors assess its income profile. We will now examine...

Goodyear Tire & Rubber (GT) reported first quarter 2026 results, with sales of US$3,881 million and a net loss of US$249 million, as tyre volumes and input costs weighed on performance. See our latest analysis for Goodyear Tire & Rubber. At a share price of US$6.86, Goodyear’s 1 day share price return of 6.03% decline and 7 day share price return of 3.11% decline came after the first quarter loss and ongoing cost pressures. The 1 year total shareholder return of 37.29% decline underlines that...

Wondering whether Clover Health Investments at US$2.82 is still a bargain or already pricing in its prospects? This breakdown will help you judge what you are really paying for. The stock has had a strong run over shorter periods, with returns of 2.5% over 7 days, 48.4% over 30 days and 17.0% year to date. However, the 1 year return sits at a 24.8% decline and the 3 year return is very large at 196.7% compared to a 61.2% decline over 5 years. Recent headlines have focused on the company as a...

National Energy Services Reunited stock reaction National Energy Services Reunited (NESR) has drawn attention after recent trading that left the stock at US$23.35, with short term moves contrasting with gains over the month and the past 3 months. See our latest analysis for National Energy Services Reunited. Although the 1 day share price return of 5.81% and 7 day share price return of 6.38% are weak, the 1 month and year to date share price returns of 7.70% and 47.88% alongside a very large...

Oil-driven sector move puts Vail Resorts (MTN) in focus Vail Resorts (MTN) climbed 3% after crude oil prices fell sharply on hopes for a deal to reopen the Strait of Hormuz, a move that could ease fuel related costs across travel and leisure stocks. See our latest analysis for Vail Resorts. Today’s move sits against a weaker backdrop, with a 30 day share price return of 3.43% and a year to date share price return of a 6.49% decline, while the 5 year total shareholder return of a 50.96%...